A detailed history of Nwam LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Nwam LLC holds 15,500 shares of CRVS stock, worth $71,765. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,500
Previous 10,050 54.23%
Holding current value
$71,765
Previous $53,000 50.94%
% of portfolio
0.01%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 04, 2025

BUY
$4.55 - $9.56 $24,797 - $52,102
5,450 Added 54.23%
15,500 $80,000
Q3 2024

Nov 12, 2024

BUY
$1.78 - $5.92 $17,889 - $59,496
10,050 New
10,050 $53,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $216M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Nwam LLC Portfolio

Follow Nwam LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nwam LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nwam LLC with notifications on news.